BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29898687)

  • 21. CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.
    Zwaenepoel K; Jacobs J; De Meulenaere A; Silence K; Smits E; Siozopoulou V; Hauben E; Rolfo C; Rottey S; Pauwels P
    Histopathology; 2017 Sep; 71(3):357-365. PubMed ID: 28383817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression in extrahepatic cholangiocarcinoma.
    Walter D; Herrmann E; Schnitzbauer AA; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S
    Histopathology; 2017 Sep; 71(3):383-392. PubMed ID: 28419539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequent PD-L1 Expression in Malignant Melanomas of the Vulva.
    Saleh B; Kriegsmann J; Falk S; Aulmann S
    Int J Gynecol Pathol; 2018 Sep; 37(5):477-481. PubMed ID: 28914674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
    Kim C; Kim EK; Jung H; Chon HJ; Han JW; Shin KH; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim SH; Kim HS
    BMC Cancer; 2016 Jul; 16():434. PubMed ID: 27393385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aligning digital CD8
    Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
    Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Status of programmed death-ligand 1 expression in sarcomas.
    Park HK; Kim M; Sung M; Lee SE; Kim YJ; Choi YL
    J Transl Med; 2018 Nov; 16(1):303. PubMed ID: 30400799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel histological examination with dynamic three-dimensional reconstruction from multiple immunohistochemically stained sections of a PD-L1-positive colon cancer.
    Korehisa S; Ikeda T; Okano S; Saeki H; Oki E; Oda Y; Hashizume M; Maehara Y
    Histopathology; 2018 Mar; 72(4):697-703. PubMed ID: 28940664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
    Calderaro J; Rousseau B; Amaddeo G; Mercey M; Charpy C; Costentin C; Luciani A; Zafrani ES; Laurent A; Azoulay D; Lafdil F; Pawlotsky JM
    Hepatology; 2016 Dec; 64(6):2038-2046. PubMed ID: 27359084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
    López JI; Pulido R; Cortés JM; Angulo JC; Lawrie CH
    Pathol Res Pract; 2018 Aug; 214(8):1110-1114. PubMed ID: 29910061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].
    Lantuejoul S; Adam J; Girard N; Duruisseaux M; Mansuet-Lupo A; Cazes A; Rouquette I; Gibault L; Garcia S; Antoine M; Vignaud JM; Galateau-Sallé F; Sagan C; Badoual C; Penault-Llorca F; Damotte D;
    Ann Pathol; 2018 Apr; 38(2):110-125. PubMed ID: 29571563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
    Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
    Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
    Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
    J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis.
    Hahn E; Liu SK; Vesprini D; Xu B; Downes MR
    J Clin Pathol; 2018 Nov; 71(11):1023-1027. PubMed ID: 30257853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
    Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
    Majzner RG; Simon JS; Grosso JF; Martinez D; Pawel BR; Santi M; Merchant MS; Geoerger B; Hezam I; Marty V; Vielh P; Daugaard M; Sorensen PH; Mackall CL; Maris JM
    Cancer; 2017 Oct; 123(19):3807-3815. PubMed ID: 28608950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions.
    Saraggi D; Galuppini F; Remo A; Urso EDL; Bacchin D; Salmaso R; Lanza C; Bao RQ; Fanelli GN; Guzzardo V; Luchini C; Scarpa M; Farinati F; Fassan M; Rugge M
    Histopathology; 2017 Sep; 71(3):470-474. PubMed ID: 28502094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.